

Oklahoma Health Care Authority
Drug Utilization Review Board
(DUR Board)
Meeting – August 10, 2011 @ 6:00 p.m.

Oklahoma Health Care Authority
2401 N.W. 23rd Street, Suite 1-A
Oklahoma City, Oklahoma 73107
Ponca Room (North Entrance)

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call To Order**
 - A. Roll Call – Dr. Graham

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
 - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
 - A. June 8, 2011 DUR Minutes – Vote
 - B. June 9, 2011 DUR Recommendation Memorandum
 - C. Correspondence

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

4. **Update on DUR / Medication Coverage Authorization Unit – See Appendix B.**
 - A. Retrospective Drug Utilization Review for April 2011
 - B. Retrospective Drug Utilization Review Response for March 2011
 - C. Medication Coverage Activity Audit for June, July 2011
 - D. Pharmacy Help Desk Activity Audit for June, July 2011

Items to be presented by Dr. Le, Dr. Phung, Dr. Muchmore, Chairman

5. **Action Item – Vote to Prior Authorize Zuplenz[®] – See Appendix C.**
 - A. Overview
 - B. COP Recommendations

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman

6. **Action Item – Annual Review of Atypical Antipsychotics – See Appendix D.**
 - A. Current Authorization Criteria
 - B. Utilization Review
 - C. Market Update
 - D. Adverse Event Questionnaire Responses
 - E. COP Recommendations
 - F. Utilization Details

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman

7. **30 Day Notice to Prior Authorize Diabetes Medications – See Appendix E.**
 - A. COP Recommendations

Items to be presented by Dr. Moore, Dr. Muchmore, Chairman

8. **30 Day Notice to Prior Authorize Berinert[®], Cinryze[®], and Kalbitor[®] – See Appendix F.**
 - A. Introduction
 - B. Treatment Options
 - C. Utilization Data
 - D. COP Recommendations
 - E. Product Details

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

9. **30 Day Notice to Prior Authorize Xiaflex[®] – See Appendix G.**
 - A. Summary of Dupuytren's Contracture
 - B. Product Summary
 - C. Utilization Data
 - D. COP Recommendations

Items to be presented by Dr. Sipols, Dr. Muchmore, Chairman

10. **Drug Utilization Review of Biologic Products for the Treatment of Rheumatoid Arthritis, Crohn's Disease, Plaque Psoriasis, and Ankylosing Spondylitis – See Appendix H.**
 - A. Product Overviews
 - B. Utilization Review
 - C. COP Recommendations
 - D. Utilization Details

Items to be presented by Dr. Graham, Dr. Muchmore, Chairman

11. **FDA and DEA Updates – See Appendix I.**
12. **Future Business**
 - A. Utilization Review of Multiple Sclerosis Agents
 - B. Annual Review of Synagis
 - C. Annual Review of Ophthalmic Products
 - D. New Product Reviews
13. **Adjournment**